JP5038582B2 - Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成 - Google Patents

Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成 Download PDF

Info

Publication number
JP5038582B2
JP5038582B2 JP2003513958A JP2003513958A JP5038582B2 JP 5038582 B2 JP5038582 B2 JP 5038582B2 JP 2003513958 A JP2003513958 A JP 2003513958A JP 2003513958 A JP2003513958 A JP 2003513958A JP 5038582 B2 JP5038582 B2 JP 5038582B2
Authority
JP
Japan
Prior art keywords
compound
structural formula
solution
phenyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003513958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502635A (ja
JP2005502635A5 (https=
Inventor
シーゲル，クレイグ
エイ． シャイマン，ジェームス
アン ネルソン，キャロル
ジェイ． ハリス，デービッド
コープランド，ダイアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
University of Michigan System
Original Assignee
Genzyme Corp
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23182463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5038582(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, University of Michigan System filed Critical Genzyme Corp
Publication of JP2005502635A publication Critical patent/JP2005502635A/ja
Publication of JP2005502635A5 publication Critical patent/JP2005502635A5/ja
Application granted granted Critical
Publication of JP5038582B2 publication Critical patent/JP5038582B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cosmetics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2003513958A 2001-07-16 2002-07-16 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成 Expired - Lifetime JP5038582B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30581401P 2001-07-16 2001-07-16
US60/305,814 2001-07-16
PCT/US2002/022659 WO2003008399A1 (en) 2001-07-16 2002-07-16 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2005112378A Division JP4708073B2 (ja) 2001-07-16 2005-04-08 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2010020146A Division JP5227348B2 (ja) 2001-07-16 2010-02-01 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成

Publications (3)

Publication Number Publication Date
JP2005502635A JP2005502635A (ja) 2005-01-27
JP2005502635A5 JP2005502635A5 (https=) 2005-12-22
JP5038582B2 true JP5038582B2 (ja) 2012-10-03

Family

ID=23182463

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2003513958A Expired - Lifetime JP5038582B2 (ja) 2001-07-16 2002-07-16 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2005112378A Expired - Lifetime JP4708073B2 (ja) 2001-07-16 2005-04-08 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2010020146A Expired - Lifetime JP5227348B2 (ja) 2001-07-16 2010-02-01 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2013041198A Pending JP2013136618A (ja) 2001-07-16 2013-02-13 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2015097734A Pending JP2015180656A (ja) 2001-07-16 2015-04-20 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2016218570A Expired - Lifetime JP6182254B2 (ja) 2001-07-16 2016-11-09 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2005112378A Expired - Lifetime JP4708073B2 (ja) 2001-07-16 2005-04-08 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2010020146A Expired - Lifetime JP5227348B2 (ja) 2001-07-16 2010-02-01 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2013041198A Pending JP2013136618A (ja) 2001-07-16 2013-02-13 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2015097734A Pending JP2015180656A (ja) 2001-07-16 2015-04-20 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2016218570A Expired - Lifetime JP6182254B2 (ja) 2001-07-16 2016-11-09 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成

Country Status (15)

Country Link
US (11) US6855830B2 (https=)
EP (3) EP2067775B1 (https=)
JP (6) JP5038582B2 (https=)
AT (2) ATE555102T1 (https=)
BE (1) BE2015C029I2 (https=)
BR (3) BR122015016313B8 (https=)
CA (1) CA2453978C (https=)
CY (1) CY2015028I2 (https=)
DK (3) DK2266968T3 (https=)
ES (3) ES2395122T3 (https=)
FR (1) FR15C0036I2 (https=)
IL (3) IL159905A0 (https=)
LU (1) LU92717I2 (https=)
PT (3) PT2266968E (https=)
WO (1) WO2003008399A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010095546A (ja) * 2001-07-16 2010-04-30 Genzyme Corp Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890949B1 (en) * 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP2004531478A (ja) 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
AU2002348261A1 (en) * 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
JP4195411B2 (ja) * 2004-04-12 2008-12-10 セイコーエプソン株式会社 有機エレクトロルミネッセンス装置の製造方法
EP1811991B1 (en) * 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
US20090088433A1 (en) * 2005-01-26 2009-04-02 Bertrand Leblond Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
SI2032134T1 (sl) 2006-05-09 2015-10-30 Genzyme Corporation Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
WO2008089403A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
US8173683B2 (en) 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
JP2010520299A (ja) * 2007-03-06 2010-06-10 アラーガン、インコーポレイテッド ３−アリール−３−ヒドロキシ−２−アミノ−プロピオン酸アミド、３−ヘテロアリール−３−ヒドロキシ−２−アミノ−プロピオン酸アミドおよび関連化合物を使用する認知障害の処置方法
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
EP2594564B1 (en) 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
CN101888840A (zh) 2007-10-05 2010-11-17 简詹姆公司 使用脑酰胺衍生物治疗多囊性肾疾病的方法
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP3078373A1 (en) 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
CN102369023A (zh) 2008-12-16 2012-03-07 建新公司 寡糖-蛋白缀合物
CA3140959A1 (en) * 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
JP5467146B2 (ja) 2010-04-16 2014-04-09 京セラ株式会社 無線通信システム、高電力基地局、低電力基地局、及び通信制御方法
MX2013012345A (es) 2011-04-22 2015-05-07 Genzyme Corp Alfa glucosidasa acida modificada con procesamiento acelerado.
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2014150043A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
JP6537500B2 (ja) 2013-09-20 2019-07-03 ビオマリン プハルマセウトイカル インコーポレイテッド 疾患治療用のグルコシルセラミドシンターゼ阻害剤
WO2015059679A1 (en) * 2013-10-25 2015-04-30 Dr. Reddy's Laboratories Limited Improved process for the preparation of eliglustat
HRP20181197T1 (hr) 2013-10-29 2018-11-30 Biomarin Pharmaceutical Inc. Derivati n-(1-hidroksi-3-(pirolidinil)propan-2-il)pirolidin-3-karboksamida kao inhibitori glukozilceramid sintaze
WO2016126572A2 (en) 2015-02-02 2016-08-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CN104557851B (zh) * 2015-02-10 2017-04-05 苏州明锐医药科技有限公司 依鲁司他的制备方法
EP3283483B1 (en) 2015-04-14 2018-12-19 Sandoz AG Crystalline eliglustat hydrochloride
WO2017068496A1 (en) * 2015-10-20 2017-04-27 Dr. Reddy' S Laboratories Limited Improved process for the preparation of eliglustat and its salts
CN105646442A (zh) * 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 一种依利格鲁司他的制备方法
EP3442514B1 (en) 2016-04-11 2021-06-16 Spedding Research Solutions Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
CN106967042B (zh) * 2017-03-21 2020-08-14 浙江奥翔药业股份有限公司 依利格鲁司他的合成方法及其中间体化合物
CN108822072B (zh) * 2017-04-11 2021-01-12 中国医学科学院药物研究所 一种制备伊力格鲁司他的方法
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
AU2018386182B2 (en) 2017-12-15 2024-03-28 Genzyme Corporation Methods for treating Gaucher disease
US12064414B2 (en) 2017-12-20 2024-08-20 Aizant Drug Research Solutions Private Limited. Stable amorphous Eliglustat premix and process for the preparation thereof
CN111217791B (zh) * 2018-11-27 2024-02-02 广东东阳光药业股份有限公司 依鲁司他中间体及其制备方法
US12398114B2 (en) 2019-03-22 2025-08-26 Piramal Pharma Limited Process for the preparation of ELIGLUSTAT and its intermediate
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
EP4048397B1 (en) 2019-10-23 2023-08-16 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors for therapeutic applications
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
EP4142878B1 (en) 2020-04-28 2024-06-26 The Regents of The University of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
CN116120274A (zh) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
WO2026006099A1 (en) 2024-06-24 2026-01-02 Genzyme Corporation Eliglustat for the treatment of gaucher disease
EP4725474A1 (en) 2024-10-11 2026-04-15 Genepharm S.A. A solid composition of eliglustat

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
JPH0416856A (ja) 1990-05-10 1992-01-21 Canon Inc 正帯電性非磁性トナー
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
HUT73527A (en) 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
JPH09508900A (ja) 1994-02-02 1997-09-09 ザ リポソーム カンパニー、インコーポレーテッド 薬理学的に活性な化合物及びリポソーム並びにそれらの使用方法
US5763438A (en) 1994-06-10 1998-06-09 Seikagaku Corporation 2-acylaminopropanol compound and medical composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
US20030073680A1 (en) * 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) * 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5916802A (en) * 1997-02-19 1999-06-29 Fritz Berthold Device for measuring ATP
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
ATE358473T1 (de) 1998-07-27 2007-04-15 Univ Johns Hopkins Diamino-propanol-verbindungen zur behandlung von ischaemien
JP2004531478A (ja) 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) * 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
EP2067775B1 (en) 2001-07-16 2012-04-25 Genzyme Corporation A N-Acylsphingosine glucosyltransferase inhibitor
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
SI2032134T1 (sl) * 2006-05-09 2015-10-30 Genzyme Corporation Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010095546A (ja) * 2001-07-16 2010-04-30 Genzyme Corp Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成

Also Published As

Publication number Publication date
FR15C0036I2 (fr) 2016-05-27
US20050222244A1 (en) 2005-10-06
BR122015016313B1 (pt) 2019-04-16
US20110003987A1 (en) 2011-01-06
PT1409467E (pt) 2012-10-24
EP1409467A1 (en) 2004-04-21
IL193244A0 (en) 2009-02-11
DK2067775T3 (da) 2012-07-16
US6855830B2 (en) 2005-02-15
US20210171507A1 (en) 2021-06-10
LU92717I2 (fr) 2015-11-24
HK1153733A1 (en) 2012-04-05
ES2395122T3 (es) 2013-02-08
ATE554082T1 (de) 2012-05-15
BE2015C029I2 (https=) 2021-07-19
IL159905A (en) 2009-05-04
WO2003008399A1 (en) 2003-01-30
PT2266968E (pt) 2013-02-25
US7763738B2 (en) 2010-07-27
ES2399323T3 (es) 2013-03-27
US20080058514A1 (en) 2008-03-06
US9546161B2 (en) 2017-01-17
CY2015028I1 (el) 2016-07-27
JP2010095546A (ja) 2010-04-30
JP5227348B2 (ja) 2013-07-03
EP2067775B1 (en) 2012-04-25
DK2266968T3 (da) 2013-04-08
BRPI0211379B8 (pt) 2021-05-25
US8779163B2 (en) 2014-07-15
BR122015016314B1 (pt) 2019-04-16
US20190322649A1 (en) 2019-10-24
JP2005255686A (ja) 2005-09-22
CY2015028I2 (el) 2016-07-27
JP2013136618A (ja) 2013-07-11
JP2005502635A (ja) 2005-01-27
US20050009872A1 (en) 2005-01-13
BR122015016313B8 (pt) 2021-05-25
DK1409467T3 (da) 2012-07-16
CA2453978A1 (en) 2003-01-30
US7265228B2 (en) 2007-09-04
EP2266968A3 (en) 2011-05-18
IL159905A0 (en) 2004-06-20
US20120296088A1 (en) 2012-11-22
EP2266968A2 (en) 2010-12-29
JP2017075151A (ja) 2017-04-20
JP4708073B2 (ja) 2011-06-22
US7196205B2 (en) 2007-03-27
PT2067775E (pt) 2012-07-16
EP2067775A1 (en) 2009-06-10
US20150148534A1 (en) 2015-05-28
US7615573B2 (en) 2009-11-10
JP6182254B2 (ja) 2017-08-16
US20030050299A1 (en) 2003-03-13
BRPI0211379B1 (pt) 2018-02-14
ES2395463T3 (es) 2013-02-15
ES2395463T4 (es) 2013-02-12
FR15C0036I1 (https=) 2015-06-26
CA2453978C (en) 2011-10-11
US20070203223A1 (en) 2007-08-30
EP1409467B1 (en) 2012-04-18
US8138353B2 (en) 2012-03-20
JP2015180656A (ja) 2015-10-15
BR122015016314B8 (pt) 2021-05-25
HK1132267A1 (en) 2010-02-19
ATE555102T1 (de) 2012-05-15
US20170334888A1 (en) 2017-11-23
EP2266968B1 (en) 2013-01-09
BR0211379A (pt) 2004-08-17

Similar Documents

Publication Publication Date Title
JP5038582B2 (ja) Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
US6835831B2 (en) Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
HK1153733B (en) Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
HK1132267B (en) A n-acylsphingosine glucosyltransferase inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090403

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091002

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20111215

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120214

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120214

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120706

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150713

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5038582

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term